Amgen/Chugai EPO ruling
Will be reviewed by the full International Trade Commission. The ITC commissioners will evaluate the Jan. 10 initial determination by ITC Administrative Law Judge Sydney Harris that would allow Chugai to continue to import erythropoietin (EPO) into the U.S. The Commission has until April 10 to make a final decision to uphold or overturn the ALJ's ruling.
You may also be interested in...
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.